Comprehensive Review
Infectious Complications in Patients With Chronic Lymphocytic Leukemia: Pathogenesis, Spectrum of Infection, and Approaches to Prophylaxis

https://doi.org/10.3816/CLM.2009.n.071Get rights and content

Abstract

Infections continue to be a major cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL), as therapeutic advances have occurred over the past several decades. The pathogenesis of infection in these patients is multifactorial, including inherent immune defects related to the primary disease process, such as hypogammaglobulinemia, as well as therapy-related immunosuppression. A characteristic spectrum of infectious complications has been described for specific treatment agents. With chlorambucil, most infections are bacterial in origin, caused by common Gram-positive and -negative organisms. Recurrent infections are a hallmark, with the respiratory tract being the most common site of infection. The pathogenesis of infection with the purine analogues is related to the quantitative and qualitative T-cell abnormalities induced by these agents. Risk factors for infection identified in patients treated with fludarabine include advanced-stage disease, prior CLL therapy, response to therapy, elevated serum creatinine, hemoglobin < 12 g/dL, and decreased serum IgG. As compared with patients receiving chlorambucil, patients receiving fludarabine have more major infections and herpes virus infections. However, Pneumocystis, Aspergillus, and cytomegalovirus (CMV) infections are uncommon. The use of alemtuzumab is complicated by frequent opportunistic infections. CMV reactivation is especially problematic, occurring in 10%–25% of patients. For prevention of infection, the use of vaccinations and immunoglobulin replacement has been studied. Recommendations for prophylactic antimicrobial therapy have arisen from CLL treatment trials and anecdotal reports. As new treatment approaches are developed for CLL, one must consider not only the efficacy of these agents for disease response but also the effect on subsequent infectious complications. Infectious complications remain a significant cause of morbidity and mortality in patients with CLL. We will review the pathogenesis as well as the spectrum of infections in these patients. We will also discuss approaches to the prophylactic and therapeutic management of infections in these patients.

References (43)

  • M Sinisalo et al.

    Similar humoral immunity parameters in chronic lymphocytic leukemia patients independent of VH gene mutation status

    Leuk Lymphoma

    (2004)
  • S Francis et al.

    The status on immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia

    Cancer

    (2006)
  • VA Morrison et al.

    Systemic and mucosal immunoglobulin levels and risk of infection in patients with chronic lymphocytic leukemia and multiple myeloma

    Blood

    (1996)
  • BD Cheson

    Infectious and immunosuppressive complications of purine analog therapy

    J Clin Oncol

    (1995)
  • VA Morrison et al.

    Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup study Cancer and Leukemia Group B 9011

    J Clin Oncol

    (2001)
  • EJ Anaissie et al.

    Infections in patients with chronic lymphocytic leukemia treated with fludarabine

    Ann Intern Med

    (1998)
  • M Hensel et al.

    Disease activity and pretreatment, rather than hypogammaglobulinemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukemia

    Br J Haematol

    (2003)
  • S O'Brien et al.

    Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia

    J Clin Oncol

    (2007)
  • M Kowal et al.

    Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory/recurrent B-cell chronic lymphocytic leukaemia (B-CLL) Polish multicentre study

    Leuk Lymphoma

    (2004)
  • JD Hainsworth et al.

    Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network

    J Clin Oncol

    (2003)
  • MJ Keating et al.

    Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

    J Clin Oncol

    (2005)
  • Cited by (104)

    • Characteristics and outcomes of COVID-19 infection in 45 patients with breast cancer: A multi-center retrospective study in Hubei, China

      2021, Breast
      Citation Excerpt :

      Only one patient had grade 3–4 leucopenia (<2.0 G/L) according to the CTCAE grading classification and none had grade 3–4 neutropenia (<1.0 G/L), preventing any inclusion of the values in the uni- or multivariate analyses. Neutropenia has been linked to the chemotherapy effects of myelosuppression [27–29], which in turn worsens the immune condition. Additionally, immunosuppression by chemotherapy possibly prolongs the time of viral shedding [30], which provides an explanation for our study, indicating that chemotherapy within 7 days may have led to myelosuppression and secondary infection, resulting in an aggravated illness and poor COVID-19 outcomes.

    • Can Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?

      2021, Hematology/Oncology Clinics of North America
      Citation Excerpt :

      Other sites of infection in order of frequency are the upper respiratory tract, genitourinary tract, blood, skin, and soft tissue, gastrointestinal tract, and central nervous system.37 The severity of hypogammaglobulinemia correlates with infection risk.38 IgG levels less than 3 g/L confer a high risk of infections and depressed IgA was associated with inferior survival independent of disease stage.39,40

    • Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study

      2020, The Lancet Oncology
      Citation Excerpt :

      They are often immunosuppressed because of their underlying illness, poor nutrition, and treatment-related side-effects. Therefore, they are at increased risk of opportunistic infections, developing severe complications, requiring admission to an intensive care unit (ICU), or even death.6–9 Liang and colleagues10 analysed data from 18 patients with cancer, from a sample of 1590 patients with COVID-19, and found a higher risk of COVID-19 and poorer outcomes in patients with cancer than in those without.

    View all citing articles on Scopus

    This summary may include the discussion of investigational and/or unlabeled uses of drugs and/or devices that may not be approved by the FDA.

    Electronic forwarding or copying is a violation of US and International Copyright Laws.

    Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1557-9190, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA. www.copyright.com 978-750-8400.

    View full text